Merck said last week its biggest tariff exposure is through Keytruda and it has enough U.S. inventory for this year. It estimated $200 million in additional costs for the levies implemented to date.
Merck wants to avoid the tariffs on Keytruda, a really high value anti-cancer drug. The tariff on those drugs would make the anti-cancer treatments even more sky-high than they already are. Merck is just lucky that people do not understand that there are other ways to treat cancer. Very effective and cheap ways to do it.
Merck wants to avoid the tariffs on Keytruda, a really high value anti-cancer drug. The tariff on those drugs would make the anti-cancer treatments even more sky-high than they already are. Merck is just lucky that people do not understand that there are other ways to treat cancer. Very effective and cheap ways to do it.